{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:54:48Z","timestamp":1791863688105,"version":"4.3.4"},"reference-count":189,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1124\/jpet.124.002287","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:35:12Z","timestamp":1727300112000},"page":"399-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury"],"prefix":"10.1016","volume":"391","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0297-199X","authenticated-orcid":false,"given":"Lauren E.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3887-004X","authenticated-orcid":false,"given":"Melanie S.","family":"Joy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.124.002287_bib1","article-title":"Review on pharmacology of cisplatin: clinical use, toxicity and mechanism of resistance of cisplatin","volume":"12","author":"Aldossary","year":"2019","journal-title":"Biomed Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.110.170084","article-title":"Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity","volume":"335","author":"Aleksunes","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.124.002287_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.toxlet.2016.07.021","article-title":"Bardoxolone methyl modulates efflux transporter and detoxifying enzyme expression in cisplatin-induced kidney cell injury","volume":"259","author":"Atilano-Roque","year":"2016","journal-title":"Toxicol Lett"},{"key":"10.1124\/jpet.124.002287_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.toxrep.2016.01.006","article-title":"Nrf2 activators as potential modulators of injury in human kidney cells","volume":"3","author":"Atilano-Roque","year":"2016","journal-title":"Toxicol Rep"},{"key":"10.1124\/jpet.124.002287_bib5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2019.10.034","article-title":"Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review","volume":"127","author":"Auer","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.124.002287_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01945-20","article-title":"The pharmacodynamic-toxicodynamic relationship of AUC and Cmax in vancomycin-induced kidney injury in an animal model","volume":"65","author":"Avedissian","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.124.002287_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039607","article-title":"MFG-E8 regulates the immunogenic potential of dendritic cells primed with necrotic cell-mediated inflammatory signals","volume":"7","author":"Baghdadi","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/jpet.124.002287_bib8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0026-895X(24)26477-4","article-title":"Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions","volume":"57","author":"Bakos","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142225","article-title":"Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: an observational cohort study","volume":"10","author":"Bhat","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/jpet.124.002287_bib10","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.ejca.2008.08.005","article-title":"Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study","volume":"44","author":"Bodnar","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.124.002287_bib11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00007691-199410000-00006","article-title":"Cisplatin pharmacokinetics in elderly patients","volume":"16","author":"Bonetti","year":"1994","journal-title":"Ther Drug Monit"},{"key":"10.1124\/jpet.124.002287_bib12","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nbt0510-436","article-title":"Next-generation biomarkers for detecting kidney toxicity","volume":"28","author":"Bonventre","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.124.002287_bib13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.coph.2010.06.003","article-title":"Modeling metastasis in the mouse","volume":"10","author":"Bos","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6904-8-7","article-title":"Long-term platinum retention after treatment with cisplatin and oxaliplatin","volume":"8","author":"Brouwers","year":"2008","journal-title":"BMC Clin Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109605","article-title":"The effect of MEK1\/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice","volume":"71","author":"Brown","year":"2020","journal-title":"Cell Signal"},{"key":"10.1124\/jpet.124.002287_bib16","first-page":"169","article-title":"Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity","volume":"67","author":"Campbell","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1124\/jpet.124.002287_bib17","series-title":"Cancer chemotherapy and biotherapy","author":"Chabner","year":"2001"},{"key":"10.1124\/jpet.124.002287_bib18","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3390\/ijms18071333","article-title":"Pharmacogenomic variants may influence the urinary excretion of novel kidney injury biomarkers in patients receiving cisplatin","volume":"18","author":"Chang","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.124.002287_bib19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2021.10.010","article-title":"The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: the prospective PLATISMA study","volume":"160","author":"Chargi","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.124.002287_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/OP.22.00710","article-title":"Cisplatin-induced ototoxicity: a concise review of the burden, prevention, and interception strategies","volume":"19","author":"Chattaraj","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1124\/jpet.124.002287_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165214","article-title":"MATE2 expression is associated with cancer cell response to metformin","volume":"11","author":"Chowdhury","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/jpet.124.002287_bib22","article-title":"Membrane transporters as mediators of cisplatin effects and side effects","volume":"2012","author":"Ciarimboli","year":"2012","journal-title":"Scientifica (Cairo)"},{"key":"10.1124\/jpet.124.002287_bib23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2353\/ajpath.2010.090610","article-title":"Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions","volume":"176","author":"Ciarimboli","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.124.002287_bib24","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0002-9440(10)61234-5","article-title":"Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter","volume":"167","author":"Ciarimboli","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.124.002287_bib25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2165\/00003088-198712030-00002","article-title":"Pharmacokinetics of anticancer drugs in children","volume":"12","author":"Crom","year":"1987","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.124.002287_bib26","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/0006-2952(85)90679-3","article-title":"The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity","volume":"34","author":"Daley-Yates","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00012.2014","article-title":"Magnesium in man: implications for health and disease","volume":"95","author":"de Baaij","year":"2015","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.124.002287_bib29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00280-023-04512-z","article-title":"Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer","volume":"91","author":"de Jong","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00280-004-0790-5","article-title":"Population pharmacokinetics of cisplatin in adult cancer patients","volume":"54","author":"de Jongh","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib31","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/sj.bjc.6600884","article-title":"Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients","volume":"88","author":"de Jongh","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.124.002287_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/fb32f1b8-7397-40be-bbf9-b80e67763043","article-title":"Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity","volume":"8","author":"DesRochers","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1124\/jpet.124.002287_bib33","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nbt.1625","article-title":"Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium","volume":"28","author":"Dieterle","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.124.002287_bib34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/jac\/dkw351","article-title":"Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis","volume":"72","author":"Downes","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/jpet.124.002287_bib35","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.072067999","article-title":"Curing metastatic testicular cancer","volume":"99","author":"Einhorn","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/jpet.124.002287_bib36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s002280100319","article-title":"Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients","volume":"57","author":"Erdlenbruch","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib37","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/COC.0000000000000301","article-title":"Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy","volume":"41","author":"Faig","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1124\/jpet.124.002287_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.579178","article-title":"Daphnetin attenuated cisplatin-induced acute nephrotoxicity with enhancing antitumor activity of cisplatin by upregulating SIRT1\/SIRT6-Nrf2 pathway","volume":"11","author":"Fan","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib39","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1007\/s00204-019-02598-0","article-title":"Kidney-based in vitro models for drug-induced toxicity testing","volume":"93","author":"Faria","year":"2019","journal-title":"Arch Toxicol"},{"key":"10.1124\/jpet.124.002287_bib40","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jpp\/rgac039","article-title":"Clonidine ameliorates cisplatin-induced nephrotoxicity: impact on OCT2 and p38 MAPK pathway","volume":"74","author":"Fawzy","year":"2022","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib41","series-title":"CISPLATIN for injection, for intravenous use","year":"1978"},{"key":"10.1124\/jpet.124.002287_bib42","series-title":"ETOPOPHOS (etoposide phosphate) for injection, for intravenous use","year":"1983"},{"key":"10.1124\/jpet.124.002287_bib43","series-title":"GEMZAR (gemcitabine for injection) powder, lyophilized, for solution for intravenous use","year":"1996"},{"key":"10.1124\/jpet.124.002287_bib44","series-title":"Clinical drug interaction studies\u2014cytochrome p450 enzyme- and transporter-mediated drug interactions","year":"2020"},{"key":"10.1124\/jpet.124.002287_bib45","series-title":"In vitro drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions","year":"2020"},{"key":"10.1124\/jpet.124.002287_bib46","series-title":"Drug development and drug interactions\u2014table of substrates, inhibitors and inducers","year":"2023"},{"key":"10.1124\/jpet.124.002287_bib47","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.2009.139","article-title":"Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity","volume":"86","author":"Filipski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.124.002287_bib48","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1038\/ncomms9715","article-title":"Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids","volume":"6","author":"Freedman","year":"2015","journal-title":"Nat Commun"},{"key":"10.1124\/jpet.124.002287_bib49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13318-017-0436-8","article-title":"Pharmacokinetic-pharmacodynamic analysis of cisplatin with hydration and mannitol diuresis: the contribution of urine cisplatin concentration to nephrotoxicity","volume":"43","author":"Fukushima","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/jpet.124.002287_bib50","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.xphs.2015.10.022","article-title":"Population pharmacokinetic-toxicodynamic modeling and simulation of cisplatin-induced acute renal injury in rats: effect of dosing rate on nephrotoxicity","volume":"105","author":"Fukushima","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.124.002287_bib51","series-title":"Testicle cancer","author":"Gaddam","year":"2023"},{"key":"10.1124\/jpet.124.002287_bib52","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/bjc.1993.221","article-title":"Cellular accumulation of the anticancer agent cisplatin: a review","volume":"67","author":"Gately","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.124.002287_bib53","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.3390\/ijms22126439","article-title":"In vitro inhibition of renal OCT2 and MATE1 secretion by antiemetic drugs","volume":"22","author":"George","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.124.002287_bib54","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/cpt.606","article-title":"Profiling of kidney injury biomarkers in patients receiving cisplatin: time-dependent changes in the absence of clinical nephrotoxicity","volume":"101","author":"George","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.124.002287_bib55","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/028418600750013447","article-title":"Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer","volume":"39","author":"Gerl","year":"2000","journal-title":"Acta Oncol"},{"key":"10.1124\/jpet.124.002287_bib56","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(00)02044-4","article-title":"Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer","volume":"355","author":"Gietema","year":"2000","journal-title":"Lancet"},{"key":"10.1124\/jpet.124.002287_bib57","series-title":"Cisplatin","author":"Gold","year":"2023"},{"key":"10.1124\/jpet.124.002287_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/140284","article-title":"On the discovery, biological effects, and use of cisplatin and metallocenes in anticancer chemotherapy","volume":"2012","author":"G\u00f3mez-Ruiz","year":"2012","journal-title":"Bioinorg Chem Appl"},{"key":"10.1124\/jpet.124.002287_bib59","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s10020-023-00733-3","article-title":"Targeted inhibition of CX3CL1 limits podocytes ferroptosis to ameliorate cisplatin-induced acute kidney injury","volume":"29","author":"Gong","year":"2023","journal-title":"Mol Med"},{"key":"10.1124\/jpet.124.002287_bib60","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1200\/JCO.1992.10.5.795","article-title":"Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity","volume":"10","author":"Gregg","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.124.002287_bib61","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/FTD.0000000000000589","article-title":"Biomarkers of drug-induced kidney toxicity","volume":"41","author":"Griffin","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1124\/jpet.124.002287_bib62","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/jso.27412","article-title":"High-dose IV magnesium in mesothelioma patients receiving surgery with hyperthermic intraoperative cisplatin: pilot studies and design of a phase II randomized clinical trial","volume":"128","author":"Gupta","year":"2023","journal-title":"J Surg Oncol"},{"key":"10.1124\/jpet.124.002287_bib63","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1211\/jpp.60.3.0006","article-title":"Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats","volume":"60","author":"Hanada","year":"2008","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib64","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1211\/0022357001777694","article-title":"Effect of buthionine sulphoximine, glutathione and methimazole on the renal disposition of cisplatin and on cisplatin-induced nephrotoxicity in rats: pharmacokinetic-toxicodynamic analysis","volume":"52","author":"Hanada","year":"2000","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib65","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1211\/0022357001777496","article-title":"Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin","volume":"52","author":"Hanada","year":"2000","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib66","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jjco\/hye040","volume":"31","author":"Hanada","year":"2001","journal-title":"Jpn J Clin Oncol"},{"key":"10.1124\/jpet.124.002287_bib67","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2014.56.0896","article-title":"Testicular cancer: a reflection on 50 years of discovery","volume":"32","author":"Hanna","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.124.002287_bib68","first-page":"173","article-title":"Nephrotoxic effects of platinum cytostatics\u2013preventative effects of nifedipine and cimetidine","volume":"95","author":"Haragsim","year":"1994","journal-title":"Sb Lek"},{"key":"10.1124\/jpet.124.002287_bib69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fphar.2015.00085","article-title":"Role of transporters in the distribution of platinum-based drugs","volume":"6","author":"Harrach","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1535370217740854","article-title":"Mouse population-based evaluation of urinary protein and miRNA biomarker performance associated with cisplatin renal injury","volume":"243","author":"Harrill","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1124\/jpet.124.002287_bib71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.diabres.2015.05.003","article-title":"SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients","volume":"109","author":"He","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1124\/jpet.124.002287_bib72","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0959-8049(02)00674-3","article-title":"Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists","volume":"39","author":"Hesketh","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.124.002287_bib73","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/(SICI)1520-670X(1998)11:1<37::AID-JTRA5>3.0.CO;2-0","article-title":"Distribution of platinum in patients treated with cisplatin determined by radiochemical neutron activation analysis","volume":"11","author":"Heydorn","year":"1998","journal-title":"J Trace Elem Exp Med"},{"key":"10.1124\/jpet.124.002287_bib74","first-page":"509","article-title":"Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects","volume":"1","author":"Hohnloser","year":"1996","journal-title":"Eur J Med Res"},{"key":"10.1124\/jpet.124.002287_bib75","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.3390\/ijms20123011","article-title":"Recent advances in models, mechanisms, biomarkers, and interventions in cisplatin-induced acute kidney injury","volume":"20","author":"Holditch","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.124.002287_bib76","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1021\/jm00121a024","article-title":"Chemical and biological properties of a new series of cis-diammineplatinum(II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor)Cl]+","volume":"32","author":"Hollis","year":"1989","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.124.002287_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/srep34845","article-title":"Bioprinting of 3D convoluted renal proximal tubules on perfusable chips","volume":"6","author":"Homan","year":"2016","journal-title":"Sci Rep"},{"issue":"Suppl 8A","key":"10.1124\/jpet.124.002287_bib78","article-title":"Central neurocircuitry associated with emesis","volume":"111","author":"Hornby","year":"2001","journal-title":"Am J Med"},{"key":"10.1124\/jpet.124.002287_bib79","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3835(87)90091-7","article-title":"Decreased cisplatin uptake by resistant L1210 leukemia cells","volume":"36","author":"Hromas","year":"1987","journal-title":"Cancer Lett"},{"key":"10.1124\/jpet.124.002287_bib80","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.fct.2012.03.059","article-title":"Eriodictyol-7-O-glucoside, a novel Nrf2 activator, confers protection against cisplatin-induced toxicity","volume":"50","author":"Hu","year":"2012","journal-title":"Food Chem Toxicol"},{"key":"10.1124\/jpet.124.002287_bib81","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00228-018-2552-z","article-title":"Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients","volume":"75","author":"Ibrahim","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib82","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","article-title":"Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals","volume":"99","author":"Ishida","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/jpet.124.002287_bib83","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1124\/mol.113.085068","article-title":"A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells","volume":"83","author":"Ivy","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib84","first-page":"3632","article-title":"Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid","volume":"44","author":"Jacobs","year":"1984","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.124.002287_bib85","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/1097-0142(19910315)67:6<1518::AID-CNCR2820670610>3.0.CO;2-3","article-title":"The use of probenecid as a chemoprotector against cisplatin nephrotoxicity","volume":"67","author":"Jacobs","year":"1991","journal-title":"Cancer"},{"key":"10.1124\/jpet.124.002287_bib86","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1039\/c3ib40049b","article-title":"Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment","volume":"5","author":"Jang","year":"2013","journal-title":"Integr Biol (Camb)"},{"key":"10.1124\/jpet.124.002287_bib87","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1523-1755.2005.67102.x","article-title":"MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis","volume":"67","author":"Jo","year":"2005","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.124.002287_bib88","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jbt.21567","article-title":"Hesperidin and rutin, antioxidant citrus flavonoids, attenuate cisplatin-induced nephrotoxicity in rats","volume":"28","author":"Kamel","year":"2014","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1124\/jpet.124.002287_bib89","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ki.2015.327","article-title":"Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition","volume":"89","author":"Katagiri","year":"2016","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.124.002287_bib90","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1248\/bpb.33.1867","article-title":"Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity","volume":"33","author":"Katsuda","year":"2010","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/jpet.124.002287_bib91","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/10601330903252206","article-title":"Population pharmacokinetics of cisplatin in Asian Indian cancer patients","volume":"26","author":"Kaushik","year":"2009","journal-title":"Clin Res Regul Aff"},{"key":"10.1124\/jpet.124.002287_bib92","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.124.002287_bib93","doi-asserted-by":"crossref","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1124\/jpet.124.002287_bib94","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.3390\/molecules25204733","article-title":"Modeling of chemoperfusion vs. intravenous administration of cisplatin in wistar rats: adsorption and tissue distribution","volume":"25","author":"Kireeva","year":"2020","journal-title":"Molecules"},{"key":"10.1124\/jpet.124.002287_bib95","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00688.2016","article-title":"Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity","volume":"313","author":"Kumar","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.124.002287_bib96","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-005-1010-7","article-title":"Magnesium depletion enhances cisplatin-induced nephrotoxicity","volume":"56","author":"Lajer","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib97","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.08070715","article-title":"Long-term renal outcomes after cisplatin treatment","volume":"11","author":"Latcha","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/jpet.124.002287_bib98","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1046\/j.1523-1755.1999.00687.x","article-title":"Apoptosis induced by cisplatin nephrotoxic injury","volume":"56","author":"Lau","year":"1999","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.124.002287_bib99","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/ki.1995.348","article-title":"Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells","volume":"48","author":"Leibbrandt","year":"1995","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.124.002287_bib100","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3892\/or.2014.3659","article-title":"G31P, CXCR1\/2 inhibitor, with cisplatin inhibits the growth of mice hepatocellular carcinoma and mitigates high-dose cisplatin-induced nephrotoxicity","volume":"33","author":"Li","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1124\/jpet.124.002287_bib101","article-title":"Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis","volume":"270","author":"Lieberthal","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.124.002287_bib102","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.7150\/ijbs.80775","article-title":"Mitophagy alleviates cisplatin-induced renal tubular epithelial cell ferroptosis through ROS\/HO-1\/GPX4 axis","volume":"19","author":"Lin","year":"2023","journal-title":"Int J Biol Sci"},{"key":"10.1124\/jpet.124.002287_bib103","series-title":"Cisplatin Chemistry and Biochemistry of a Leading Anticancer Drug","author":"Lippert","year":"1999"},{"key":"10.1124\/jpet.124.002287_bib104","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.124.002287_bib105","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2147\/TCRM.S165531","article-title":"The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly","volume":"14","author":"Liu","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1124\/jpet.124.002287_bib106","article-title":"Exploration of the protective mechanisms of Icariin against cisplatin-induced renal cell damage in canines","volume":"11","author":"Liu","year":"2024","journal-title":"Front Vet Sci"},{"key":"10.1124\/jpet.124.002287_bib107","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3389\/fphys.2018.01898","article-title":"Cisplatin-membrane interactions and their influence on platinum complexes activity and toxicity","volume":"9","author":"Martinho","year":"2018","journal-title":"Front Physiol"},{"key":"10.1124\/jpet.124.002287_bib108","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/cancers13071572","article-title":"Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations","volume":"13","author":"McSweeney","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1124\/jpet.124.002287_bib109","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1172\/JCI1497","article-title":"Induction of p21WAF1\/CIP1\/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure","volume":"101","author":"Megyesi","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.124.002287_bib110","doi-asserted-by":"crossref","first-page":"794","DOI":"10.2174\/1568009614666141128105146","article-title":"Interactions of cisplatin with non-DNA targets and their influence on anticancer activity and drug toxicity: the complex world of the platinum complex","volume":"14","author":"Mezencev","year":"2015","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1124\/jpet.124.002287_bib111","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.lfs.2019.03.008","article-title":"beta-Hydroxybutyrate, a ketone body, reduces the cytotoxic effect of cisplatin via activation of HDAC5 in human renal cortical epithelial cells","volume":"222","author":"Mikami","year":"2019","journal-title":"Life Sci"},{"key":"10.1124\/jpet.124.002287_bib112","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00280-020-04147-4","article-title":"Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction","volume":"86","author":"Morita-Ogawa","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib113","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/nbt.3392","article-title":"Nephron organoids derived from human pluripotent stem cells model kidney development and injury","volume":"33","author":"Morizane","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.124.002287_bib114","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/ki.2013.374","article-title":"Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative Consensus Conference","volume":"85","author":"Murray","year":"2014","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.124.002287_bib115","doi-asserted-by":"crossref","DOI":"10.1002\/j.1875-9114.1997.tb03816.x","article-title":"Comparative clinical pharmacology of cisplatin and carboplatin","volume":"17","author":"Murry","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1124\/jpet.124.002287_bib116","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s002800050548","article-title":"Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients","volume":"39","author":"Nagai","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s002800050618","article-title":"Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo","volume":"40","author":"Nagai","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib118","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1177\/009127009803801107","article-title":"Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program","volume":"38","author":"Nagai","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib119","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.bcp.2010.08.019","article-title":"Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity","volume":"80","author":"Nakamura","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib120","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"10.1124\/jpet.124.002287_bib121","first-page":"849","article-title":"Mechanisms for the renal secretion of cisplatin","volume":"68","author":"Nelson","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"10.1124\/jpet.124.002287_bib122","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1124\/dmd.117.079384","article-title":"Expression of organic anion transporter 1 or 3 in human kidney proximal tubule cells reduces cisplatin sensitivity\u2019","volume":"46","author":"Nieskens","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"Suppl","key":"10.1124\/jpet.124.002287_bib123","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003495-200059004-00003","article-title":"Clinical pharmacokinetics and administration of established platinum drugs","volume":"59","author":"O\u2019Dwyer","year":"2000","journal-title":"Drugs"},{"key":"10.1124\/jpet.124.002287_bib124","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3892\/mco.2020.2127","article-title":"Risk factors for cisplatin-induced acute kidney injury: a pilot study on the usefulness of genetic variants for predicting nephrotoxicity in clinical practice","volume":"13","author":"Oda","year":"2020","journal-title":"Mol Clin Oncol"},{"key":"10.1124\/jpet.124.002287_bib125","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/ki.2013.330","article-title":"Pharmacological activation of NQO1 increases NAD+ levels and attenuates cisplatin-mediated acute kidney injury in mice","volume":"85","author":"Oh","year":"2014","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.124.002287_bib126","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5049\/EBP.2014.12.2.55","article-title":"Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies","volume":"12","author":"Oh","year":"2014","journal-title":"Electrolyte Blood Press"},{"key":"10.1124\/jpet.124.002287_bib127","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.19209","article-title":"Recommendations on acute kidney injury biomarkers from the acute Disease Quality Initiative Consensus Conference: a consensus statement","volume":"3","author":"Ostermann","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1124\/jpet.124.002287_bib128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2017.05.063","article-title":"Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node?","volume":"811","author":"Oun","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib129","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/967826","article-title":"Pathophysiology of cisplatin-induced acute kidney injury","volume":"2014","author":"Ozkok","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1124\/jpet.124.002287_bib130","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.90545.2008","article-title":"The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity","volume":"296","author":"Pabla","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.124.002287_bib131","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00079-19","article-title":"Comparative performance of urinary biomarkers for vancomycin-induced kidney injury according to timeline of injury","volume":"63","author":"Pais","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.124.002287_bib132","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/toxsci\/kfw077","article-title":"Detection of drug-induced acute kidney injury in humans using urinary KIM-1, miR-21, -200c, and -423","volume":"152","author":"Pavkovic","year":"2016","journal-title":"Toxicol Sci"},{"key":"10.1124\/jpet.124.002287_bib133","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/B978-0-12-800223-0.00006-2","article-title":"SLC22, SLC44, and SLC47 transporters\u2014organic anion and cation transporters: molecular and cellular properties","volume":"73","author":"Pelis","year":"2014","journal-title":"Curr Top Membr"},{"key":"10.1124\/jpet.124.002287_bib134","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.taap.2015.12.002","article-title":"Application of small RNA sequencing to identify microRNAs in acute kidney injury and fibrosis","volume":"312","author":"Pellegrini","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib135","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4103\/0971-5851.125262","article-title":"Cisplatin induced paroxysmal supraventricular tachycardia","volume":"34","author":"Raja","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1124\/jpet.124.002287_bib136","article-title":"Cisplatin concentrations in long and short duration infusion: implications for the optimal time of radiation delivery","volume":"10","author":"Rajkumar","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1124\/jpet.124.002287_bib137","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00101.2003","article-title":"TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure","volume":"285","author":"Ramesh","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.124.002287_bib138","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/943618","article-title":"Management of chemotherapy induced nausea and vomiting in patients on multiday cisplatin based combination chemotherapy","volume":"2015","author":"Ranganath","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1124\/jpet.124.002287_bib139","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00040.2017","article-title":"IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer","volume":"314","author":"Ravichandran","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.124.002287_bib140","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00109-015-1366-z","article-title":"CD4 T cell knockout does not protect against kidney injury and worsens cancer","volume":"94","author":"Ravichandran","year":"2016","journal-title":"J Mol Med"},{"key":"10.1124\/jpet.124.002287_bib141","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1987.5.2.304","article-title":"Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity","volume":"5","author":"Reece","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.124.002287_bib142","series-title":"Compendium of Pharmaceuticals and Specialites","author":"Repchinsky","year":"2004"},{"key":"10.1124\/jpet.124.002287_bib143","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/cc11240","article-title":"Subclinical AKI is still AKI\u2019","volume":"16","author":"Ronco","year":"2012","journal-title":"Crit Care"},{"key":"10.1124\/jpet.124.002287_bib144","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/205698a0","article-title":"Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode","volume":"205","author":"Rosenberg","year":"1965","journal-title":"Nature"},{"key":"10.1124\/jpet.124.002287_bib145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/222385a0","article-title":"Platinum compounds: a new class of potent antitumour agents","volume":"222","author":"Rosenberg","year":"1969","journal-title":"Nature"},{"key":"10.1124\/jpet.124.002287_bib146","first-page":"781","article-title":"Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid","volume":"63","author":"Ross","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1124\/jpet.124.002287_bib147","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3389\/fphar.2018.00638","article-title":"mangiferin ameliorates cisplatin induced acute kidney injury by upregulating Nrf-2 via the activation of PI3K and exhibits synergistic anticancer activity with cisplatin","volume":"9","author":"Sadhukhan","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib148","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00685736","article-title":"Long-term platinum excretion in patients treated with cisplatin","volume":"36","author":"Schierl","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib149","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/biomedicines9081033","article-title":"In vitro nephrotoxicity studies of established and experimental platinum-based compounds","volume":"9","author":"Schoch","year":"2021","journal-title":"Biomedicines"},{"key":"10.1124\/jpet.124.002287_bib150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.14573\/altex.1710181","article-title":"RPTEC\/TERT1 cells form highly differentiated tubules when cultured in a 3D matrix","volume":"35","author":"Secker","year":"2018","journal-title":"ALTEX"},{"key":"10.1124\/jpet.124.002287_bib151","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis\u2019","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"10.1124\/jpet.124.002287_bib152","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00512.2015","article-title":"Repeated administration of low-dose cisplatin in mice induces fibrosis","volume":"310","author":"Sharp","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.124.002287_bib153","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00636.2017","article-title":"Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease","volume":"315","author":"Sharp","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.124.002287_bib154","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"10.1124\/jpet.124.002287_bib700","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1124\/jpet.124.002287_bib155","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1002\/1097-0142(19871201)60:11<2823::AID-CNCR2820601138>3.0.CO;2-C","article-title":"The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man","volume":"60","author":"Sleijfer","year":"1987","journal-title":"Cancer"},{"key":"10.1124\/jpet.124.002287_bib156","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.toxlet.2012.12.015","article-title":"In vitro evaluation of biomarkers for cisplatin-induced nephrotoxicity using HK-2 human kidney epithelial cells","volume":"217","author":"Sohn","year":"2013","journal-title":"Toxicol Lett"},{"key":"10.1124\/jpet.124.002287_bib157","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00127.2014","article-title":"Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation","volume":"307","author":"Solanki","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.124.002287_bib158","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00096.2015","article-title":"Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice","volume":"309","author":"Solanki","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.124.002287_bib159","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41581-018-0003-9","article-title":"Advances in predictive in vitro models of drug-induced nephrotoxicity","volume":"14","author":"Soo","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1124\/jpet.124.002287_bib160","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/clpt.2013.145","article-title":"Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance","volume":"94","author":"Sprowl","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.124.002287_bib161","doi-asserted-by":"crossref","DOI":"10.21037\/apm.2017.03.05","article-title":"Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation","volume":"6","author":"Stinson","year":"2017","journal-title":"Ann Palliat Med"},{"key":"10.1124\/jpet.124.002287_bib162","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/0006-291X(89)92225-0","article-title":"Adverse effects of anti-tumor drug, cisplatin, on rat kidney mitochondria: disturbances in glutathione peroxidase activity","volume":"159","author":"Sugiyama","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.124.002287_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100351","article-title":"Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study)","volume":"7","author":"Suppadungsuk","year":"2022","journal-title":"ESMO Open"},{"key":"10.1124\/jpet.124.002287_bib164","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1208\/s12248-018-0245-2","article-title":"Combining extracellular miRNA determination with microfluidic 3D Cell cultures for the assessment of nephrotoxicity: a proof of concept study","volume":"20","author":"Suter-Dick","year":"2018","journal-title":"AAPS J"},{"key":"10.1124\/jpet.124.002287_bib165","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature15695","article-title":"Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis","volume":"526","author":"Takasato","year":"2015","journal-title":"Nature"},{"key":"10.1124\/jpet.124.002287_bib166","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.3390\/ijms20205238","article-title":"The predictive role of the biomarker kidney molecule-1 (KIM-1) in acute kidney injury (AKI) cisplatin-induced nephrotoxicity","volume":"20","author":"Tanase","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.124.002287_bib167","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/0004563214528312","article-title":"Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage?","volume":"52","author":"Tekce","year":"2015","journal-title":"Ann Clin Biochem"},{"key":"10.1124\/jpet.124.002287_bib168","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1681\/ASN.2015010079","article-title":"Three-Dimensional morphology by multiphoton microscopy with clearing in a model of cisplatin-induced CKD","volume":"27","author":"Torres","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.124.002287_bib169","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/0959-8049(92)90519-8","article-title":"The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy","volume":"28A","author":"Tothill","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.124.002287_bib170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biopha.2008.08.004","article-title":"Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity","volume":"63","author":"Townsend","year":"2009","journal-title":"Biomed Pharmacother"},{"key":"10.1124\/jpet.124.002287_bib171","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1173578","article-title":"Acute kidney injury and acute kidney disease in high-dose cisplatin-treated head and neck cancer","volume":"13","author":"Trevisani","year":"2023","journal-title":"Front Oncol"},{"key":"10.1124\/jpet.124.002287_bib172","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1365-2125.2004.02082.x","article-title":"Population pharmacokinetics of total and unbound plasma cisplatin in adult patients","volume":"57","author":"Urien","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib173","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ndt\/gfs499","article-title":"Cisplatin-induced injury of the renal distal convoluted tubule is associated with hypomagnesaemia in mice","volume":"28","author":"van Angelen","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.124.002287_bib174","doi-asserted-by":"crossref","DOI":"10.1177\/09603271211047915","article-title":"Wedelolactone protects against cisplatin-induced nephrotoxicity in mice via inhibition of organic cation transporter","volume":"40","author":"Wang","year":"2021","journal-title":"Hum Exp Toxicol"},{"key":"10.1124\/jpet.124.002287_bib175","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3390\/metabo13121173","article-title":"Baicalin exhibits a protective effect against cisplatin-induced cytotoxic damage in canine renal tubular epithelial cells","volume":"13","author":"Wang","year":"2023","journal-title":"Metabolites"},{"key":"10.1124\/jpet.124.002287_bib176","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/FPC.0000000000000156","article-title":"Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202","volume":"25","author":"Wanga","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/jpet.124.002287_bib177","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jtemb.2014.01.001","article-title":"Assessing the intracellular concentration of platinum in medulloblastoma cell lines after Cisplatin incubation","volume":"28","author":"Wehe","year":"2014","journal-title":"J Trace Elem Med Biol"},{"key":"10.1124\/jpet.124.002287_bib178","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.ki.5002256","article-title":"The pathological role of Bax in cisplatin nephrotoxicity","volume":"72","author":"Wei","year":"2007","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.124.002287_bib179","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.ajpath.2014.01.025","article-title":"Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice","volume":"184","author":"Wen","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.124.002287_bib180","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1021\/jm3002857","article-title":"In vitro anticancer activity of cis-diammineplatinum(II) complexes with beta-diketonate leaving group ligands","volume":"55","author":"Wilson","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.124.002287_bib181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2019.02.015","article-title":"Identification of microRNA-mRNA networks involved in cisplatin-induced renal tubular epithelial cells injury","volume":"851","author":"Wu","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib182","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1208\/s12248-020-00489-2","article-title":"PKPD modeling and dosing considerations in advanced ovarian cancer patients treated with cisplatin-based intraoperative intraperitoneal chemotherapy","volume":"22","author":"Xie","year":"2020","journal-title":"AAPS J"},{"key":"10.1124\/jpet.124.002287_bib183","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00520-016-3512-8","article-title":"Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis","volume":"25","author":"Yamaguchi","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1124\/jpet.124.002287_bib184","first-page":"2199","article-title":"Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin\u2019","volume":"35","author":"Yamamoto","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1124\/jpet.124.002287_bib185","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00590.2007","article-title":"Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells","volume":"294","author":"Yang","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.124.002287_bib186","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.3390\/ijms21197023","article-title":"Prediction of cyclosporin-mediated drug interaction using physiologically based pharmacokinetic model characterizing interplay of drug transporters and enzymes","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.124.002287_bib187","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.bcp.2005.09.020","article-title":"\u2018Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat\u2019","volume":"70","author":"Yonezawa","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.124.002287_bib188","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1369\/0022155412446227","article-title":"isplatin nephrotoxicity involves mitochondrial injury with impaired tubular mitochondrial enzyme activity","volume":"60","author":"Zsengell\u00e9r","year":"2012","journal-title":"J Histochem Cytochem"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524178238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524178238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.124.002287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:38:29Z","timestamp":1739979509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524178238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":189,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0022356524178238"],"URL":"https:\/\/doi.org\/10.1124\/jpet.124.002287","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.124.002287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}